Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Update on polycystic ovary syndrome

  • Kim, Jin Ju (Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, Seoul National University Hospital and the Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine)
  • Received : 2020.12.16
  • Accepted : 2021.05.12
  • Published : 2021.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Polycystic ovary syndrome (PCOS) is a common disorder in reproductive-age women. In 2018, an international evidence-based guideline announced recommendations spanning a wide range of issues on the assessment and management of PCOS. From the 166 recommendations, the present study reviews those that are of particular clinical relevance for daily practice and introduces other relevant studies that have been published since the global guideline. The 2018 guideline increased the antral follicle count cutoff for the diagnosis of PCOS from 12 to 20 when using a high-frequency probe. Hirsutism was defined as having a score of ≥4-6 based on a lower percentile of 85%-90% or cluster analysis, which was lower than the traditionally used 95th percentile-based cutoff. The diagnosis of PCOS in adolescents is challenging, and irregular menstruation was defined carefully according to years from menarche. The use of ultrasonography for the diagnosis of PCOS was restricted to those 8 years after menarche. As medication for non-fertility indications, combined oral contraceptives are the first-line drug. Metformin, in addition to lifestyle modifications, should be considered for adult patients with a body mass index ≥25 kg/m2 for the management of weight and metabolic outcomes. An aromatase inhibitor is the recommended first-line medication for ovulation induction, a subsequent individual patient data meta-analysis also reported the same conclusion. Whether the new global guideline will be fully adopted by many specialists and change clinical practice is open to question. Further studies are needed to better understand and manage PCOS patients well.

Keywords

References

  1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-18. https://doi.org/10.1093/humrep/dey256
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7. https://doi.org/10.1093/humrep/deh098
  3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88. https://doi.org/10.1016/j.fertnstert.2008.06.035
  4. Kim JJ, Hwang KR, Choi YM, Moon SY, Chae SJ, Park CW, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril 2014;101:1424-30. https://doi.org/10.1016/j.fertnstert.2014.01.049
  5. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG 2009;116:1633-9. https://doi.org/10.1111/j.1471-0528.2009.02347.x
  6. Cui L, Zhao H, Zhang B, Qu Z, Liu J, Liang X, et al. Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum Reprod 2013;28:538-44. https://doi.org/10.1093/humrep/des424
  7. Kim JJ, Hwang KR, Chae SJ, Yoon SH, Choi YM. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome. Hum Reprod 2020;35:652-9. https://doi.org/10.1093/humrep/deaa012
  8. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30. https://doi.org/10.1016/0002-9378(81)90746-8
  9. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod 2011;26:214-20. https://doi.org/10.1093/humrep/deq303
  10. Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS Committee. J Clin Endocrinol Metab 2019;104:2875-91. https://doi.org/10.1210/jc.2018-02548
  11. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92. https://doi.org/10.1210/jc.2013-2350
  12. Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update 2018;24:455-67. https://doi.org/10.1093/humupd/dmy007
  13. Choi YM, Hwang KR, Oh SH, Lee D, Chae SJ, Yoon SH, et al. Progression to prediabetes or diabetes in young Korean women with polycystic ovary syndrome: a longitudinal observational study. Clin Endocrinol (Oxf) 2021;94:837-44. https://doi.org/10.1111/cen.14416
  14. Koo BK, Lee CH, Yang BR, Hwang SS, Choi NK. The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a National Health Insurance Database Study. PLoS One 2014;9:e110650. https://doi.org/10.1371/journal.pone.0110650
  15. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl 1):S13-28. https://doi.org/10.2337/dc19-S002
  16. Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: ethnic differences. J Obstet Gynaecol Res 2019;45:2330-7. https://doi.org/10.1111/jog.14132
  17. Lo JC, Yang J, Gunderson EP, Hararah MK, Gonzalez JR, Ferrara A. Risk of type 2 diabetes mellitus following gestational diabetes pregnancy in women with polycystic ovary syndrome. J Diabetes Res 2017;2017:5250162.
  18. Ferrara A, Kahn HS, Quesenberry CP, Riley C, Hedderson MM. An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet Gynecol 2004;103:526-33. https://doi.org/10.1097/01.AOG.0000113623.18286.20
  19. Han AR, Kim HO, Cha SW, Park CW, Kim JY, Yang KM, et al. Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome: a case-control study. Clin Exp Reprod Med 2011;38:103-8. https://doi.org/10.5653/cerm.2011.38.2.103
  20. World Health Organization; Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000.
  21. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018;12:CD012378.
  22. Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. Firstline ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update 2019;25:717-32. https://doi.org/10.1093/humupd/dmz029